Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Public ClinicalTrials.gov record NCT03608033. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2 g/day) assessed at 36 weeks from baseline.
Study identification
- NCT ID
- NCT03608033
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2018
- Primary completion
- Jan 11, 2024
- Completion
- Jan 11, 2024
- Last update posted
- Dec 8, 2025
2018 – 2024
United States locations
- U.S. sites
- 34
- U.S. states
- 18
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Omeros Investigational Site | Florence | Alabama | 35630 | — |
| Omeros Investigational Site | Mesa | Arizona | 85206 | — |
| Omeros Investigation Sites | Phoenix | Arizona | 85016 | — |
| Omeros Investigational Site | Scottsdale | Arizona | 85258 | — |
| Omeros Investigational Site | Scottsdale | Arizona | 85259 | — |
| Omeros Investigational Site | Los Angeles | California | 90022-4302 | — |
| Omeros Investigational Site | Los Angeles | California | 90025 | — |
| Omeros Investigational Site | Northridge | California | 91324 | — |
| Omeros Investigational Site | San Dimas | California | 91773 | — |
| Omeros Investigational Site | San Francisco | California | 94118 | — |
| Omeros Investigational Site | Stanford | California | 94304 | — |
| Omeros Investigational Site | Torrance | California | 90509 | — |
| Omeros Investigational Site | Denver | Colorado | 80230 | — |
| Omeros Investigational Site | Miami | Florida | 33136 | — |
| Omeros Investigational Site | Miami Lakes | Florida | 33014 | — |
| Omeros Investigational Site | Lawrenceville | Georgia | 30046 | — |
| Omeros Investigational Site | Chicago | Illinois | 60612 | — |
| Omeros Investigational Site | Iowa City | Iowa | 52242 | — |
| Omeros Investigational Site | Boston | Massachusetts | 02111 | — |
| Omeros Investigational Site | Springfield | Massachusetts | 01107 | — |
| Omeros Investigational Site | Minneapolis | Minnesota | 55414 | — |
| Omeros Investigational Site | Rochester | Minnesota | 55905 | — |
| Omeros Investigational Site | St Louis | Missouri | 63110 | — |
| Omeros Investigational Site | Fresh Meadows | New York | 11365 | — |
| Omeros Investigational Site | New York | New York | 10029 | — |
| Omeros Investigational Site | Cincinnati | Ohio | 45220 | — |
| Omeros Investigational Site | Columbus | Ohio | 43210 | — |
| Omeros Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Omeros Investigational Site | Charleston | South Carolina | 29425 | — |
| Omeros Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Omeros Investigational Site | Amarillo | Texas | 79106 | — |
| Omeros Investigational Site | Dallas | Texas | 75246 | — |
| Omeros Investigational Site | Houston | Texas | 77054 | — |
| Omeros Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03608033, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03608033 live on ClinicalTrials.gov.